FDA Approves First Drug for Treatment of Tardive Dyskinesia

Share this content:
FDA Approves First Drug for Treatment of Tardive Dyskinesia
FDA Approves First Drug for Treatment of Tardive Dyskinesia

WEDNESDAY, April 12, 2017 (HealthDay News) -- Ingrezza (valbenazine), the first drug to treat adults with tardive dyskinesia, has been approved by the U.S. Food and Drug Administration.

Ingrezza's effectiveness was established in a clinical study of 234 individuals that compared the drug to a placebo. After six weeks, participants who received Ingrezza had improvement in the severity of abnormal involuntary movements.

Potential side effects included sleepiness and QT prolongation. Anyone taking Ingrezza should not drive or use heavy machinery until the effects of the drug on the person are known, the FDA warned.

"Tardive dyskinesia can be disabling and can further stigmatize patients with mental illness," Mitchell Mathis, M.D., director of the FDA's Division of Psychiatry Products, said in a statement. "Approving the first drug for the treatment of tardive dyskinesia is an important advance for patients suffering with this condition."

Approval of Ingrezza was given to Neurocrine Biosciences, based in San Diego.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

From pre- to post-expansion period, 59 percent relative increase in Medicaid-covered preemptive listings

BCG Vaccine Tied to Reduced Hyperglycemia in Type 1 Diabetes

BCG Vaccine Tied to Reduced Hyperglycemia in Type ...

Systemic shift in glucose metabolism from oxidative phosphorylation to aerobic glycolysis

Many Physicians Not Prepared for End-of-Life Talks With Patients

Many Physicians Not Prepared for End-of-Life Talks With ...

Additional training, reimbursement may foster these critical conversations, authors say

is free, fast, and customized just for you!




Already a member?

Sign In Now »